Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bcr-2020-238210 http://scihub22266oqcxt.onion/10.1136/bcr-2020-238210 33419750!7798428!33419750     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33419750&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMJ+Case+Rep 2021 ; 14 (1): ä Nephropedia Template TP {{tp|p=33419750|t=2021. Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab |pdf=|usr=}}{{33419750}} gab.com Text Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab JO: BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33419750 #FOAvip As of 28 October 2020, there are over 44 000 000 confirmed COVID-19 infections and over 1 000 000 deaths worldwide, including 945 367 infections and 45 765 deaths in the UK. Acute respiratory distress syndrome occurs in 50% of patients with secondary haemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome characterised by a surge of cytokines, including interleukin 6 (IL-6). Here we describe the case of the first patient with severe COVID-19 pneumonia successfully treated with tocilizumab, a humanised monoclonal antibody against the IL-6 receptor, in the UK. Early treatment (after 7-10 days from the onset of symptoms) with tocilizumab could (1) reduce the risk of requiring non-invasive or invasive ventilation; (2) offer a chance of survival to people who are not fit for escalation or have refused to be ventilated; and (3) potentially increase the chance of survival in some patients who are already ventilated but fail to improve with supportive treatment. Twit Text FOAVip Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab ????BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33419750 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33419750 #FOAvip English Wikipedia <ref>{{Cite pmid|33419750}}</ref> Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab #MMPMID33419750 Gentile G; Davies R; Manfreda VM; Ul Abideen Z BMJ Case Rep 2021[Jan]; 14 (1): ä PMID33419750show ga As of 28 October 2020, there are over 44 000 000 confirmed COVID-19 infections and over 1 000 000 deaths worldwide, including 945 367 infections and 45 765 deaths in the UK. Acute respiratory distress syndrome occurs in 50% of patients with secondary haemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome characterised by a surge of cytokines, including interleukin 6 (IL-6). Here we describe the case of the first patient with severe COVID-19 pneumonia successfully treated with tocilizumab, a humanised monoclonal antibody against the IL-6 receptor, in the UK. Early treatment (after 7-10 days from the onset of symptoms) with tocilizumab could (1) reduce the risk of requiring non-invasive or invasive ventilation; (2) offer a chance of survival to people who are not fit for escalation or have refused to be ventilated; and (3) potentially increase the chance of survival in some patients who are already ventilated but fail to improve with supportive treatment. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |COVID-19/complications/physiopathology[MESH] |Diabetes Mellitus, Type 2/complications[MESH] |Humans[MESH] |Hypertension/complications[MESH] |Hypoxia/physiopathology/*therapy[MESH] |Male[MESH] |Oxygen Inhalation Therapy[MESH] |Receptors, Interleukin-6/antagonists & inhibitors[MESH] |SARS-CoV-2[MESH]Successful treatment of severe COVID-19 pneumonia and hyperinflammator(epmc).pdf DeepDyve Pubget Overpricing